Results: 5

1.
Figure 2.

Figure 2. From: Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR.

Long-term outcomes in each randomized group in participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Mahboob Rahman, et al. Clin J Am Soc Nephrol. 2012 June;7(6):989-1002.
2.
Figure 1.

Figure 1. From: Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR.

Participant flow for long-term follow-up of participants in the ALLHAT participants. ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; eGFR, estimated GFR.

Mahboob Rahman, et al. Clin J Am Soc Nephrol. 2012 June;7(6):989-1002.
3.
Figure 3.

Figure 3. From: Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR.

Adjusted all-cause mortality by baseline eGFR strata. Adjusted for age, race, sex, baseline diabetes status, baseline systolic BP, and cardiovascular disease before trial entry. eGFR, estimated GFR.

Mahboob Rahman, et al. Clin J Am Soc Nephrol. 2012 June;7(6):989-1002.
4.
Figure 4.

Figure 4. From: Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR.

Cardiovascular disease mortality by baseline estimated GFR (eGFR) stratum. (A) Cardiovascular disease mortality by treatment group for all participants. (B) Rates for participants with eGFR≥90 ml/min per 1.73 m2. (C) Rates for participants with eGFR=60–89 ml/min per 1.73 m2. (D) Rates for participants with eGFR<60 ml/min per 1.73 m2.

Mahboob Rahman, et al. Clin J Am Soc Nephrol. 2012 June;7(6):989-1002.
5.
Figure 5.

Figure 5. From: Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR.

ESRD by baseline estimated GFR (eGFR) stratum. (A) ESRD rates by treatment group for all participants; (B) rates for participants with eGFR ≥ 90 ml/min per 1.73 m2; (C) rates for participants with eGFR 60-89 ml/min per 1.73 m2; (D) rates for participants with eGFR < 60 ml/min per 1.73 m2.

Mahboob Rahman, et al. Clin J Am Soc Nephrol. 2012 June;7(6):989-1002.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk